European Patent no EP 1728507 - notice of oppsition
NattoPharma has been notified today by the European Patent Office that a notice of opposition was filed against European Patent no. EP 1728507. NattoPharma has noted that many of the objections raised already have been discussed in writing and orally with the Examining Division of the EPO prior to grant and will defend the patent in the opposition proceeding to come.
About NattoPharma
NattoPharma, Norway is the exclusive international supplier of MenaQ7, the natural vitamin K2. NattoPharma has entered into a multi-year research and development program to substantiate and discover the health benefits of natural vitamin K2 for applications in the exciting marketplace for functional food and health food supplements.
Please visit www.nattopharma.com
About MenaQ7
MenaQ7 provides natural vitamin K2 as a fermentation extract whereby vitamin K2 is manufactured using bascillus subtilis natto. This process has the capacity of producing the highly pure and bio-available form of vitamin K2, menaquinone-7 (MK-7). MenaQ7 is the best documented, commercially available natural vitamin K2 with guaranteed actives and stability, clinical substantiation and international patents granted and pending.
For more information on the health benefits of MenaQ7, please visit www.menaq7.com
For more information, please contact:CEO Peter Carlsson
NattoPharma ASA
Phone: +47 950 499 06